HUTCHMED (China) Limited

HKEX:0013.HK

27.85 (HKD) • At close September 5, 2024
Bedrijfsnaam HUTCHMED (China) Limited
Symbool 0013.HK
Munteenheid HKD
Prijs 27.9
Beurswaarde 24,314,004,630
Dividendpercentage 0%
52-weken bereik 19 - 35.9
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Wei-Guo Su B.Sc., Ph.D.
Website https://www.hutch-med.com

An error occurred while fetching data.

Over HUTCHMED (China) Limited

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric

Vergelijkbare Aandelen

Jinxin Fertility Group Limited logo

Jinxin Fertility Group Limited

1951.HK

2.23 HKD

RemeGen Co., Ltd. logo

RemeGen Co., Ltd.

9995.HK

12.46 HKD

3SBio Inc. logo

3SBio Inc.

1530.HK

5.84 HKD

Shanghai Haohai Biological Technology Co., Ltd. logo

Shanghai Haohai Biological Technology Co., Ltd.

6826.HK

40.05 HKD

Jiangsu Recbio Technology Co., Ltd. logo

Jiangsu Recbio Technology Co., Ltd.

2179.HK

8.8 HKD

Sihuan Pharmaceutical Holdings Group Ltd. logo

Sihuan Pharmaceutical Holdings Group Ltd.

0460.HK

0.55 HKD

LifeTech Scientific Corporation logo

LifeTech Scientific Corporation

1302.HK

1.39 HKD

SSY Group Limited logo

SSY Group Limited

2005.HK

3.86 HKD

Grand Pharmaceutical Group Limited logo

Grand Pharmaceutical Group Limited

0512.HK

4.44 HKD

Akeso, Inc. logo

Akeso, Inc.

9926.HK

48.2 HKD

Financiële Gegevens

Cijfers zijn in miljoenen (HKD)

Cijfers zijn in miljoenen (HKD)